Search results

Selected filters:

Life Sciences

Article type




889 results found for your search

Sort options
25 September 2015

It’s 4-0 pharma as another investor IPR challenge fails, but this issue is not going away

As anyone keeping the IPR score will know, so far it’s pharma 4 - investor community 0. After the Coalition for Affordable Drugs, the entity formed by hedge fund manager Kyle Bass and IPNav founder Erich Spangenberg, saw the first three of its IPRs…

29 October 2015

China still lags behind when it comes to bringing science-based innovations to market

A new report from the McKinsey Global Institute (MGI) examining China’s innovation record confirms that despite gains made in consumer electronics offerings, Chinese companies are struggling to bring technologies to market in many science and…

10 January 2015

NPE suits in the US down significantly in 2014 and figures make it clear that SMEs are very much a secondary target

The 2014 Patent Litigation Report published earlier this week by Unified Patents is a treasure trove of statistics. Not surprisingly for a firm whose business model is focused on helping clients defend against “frivolous lawsuits” primarily…

09 January 2015

An IPR warning shot for pharma that could resonate far and wide

Earlier this week US hedge fund investor Kyle Bass got the wires buzzing when he reportedly outlined his plans to wage an inter partes review (IPR) war on big pharma at the USPTO’s Patent Trial and Appeal Board (PTAB). According to Bass,…

09 January 2015

Draft Indian IP strategy aims to kickstart patent market

India’s six-member IPR Think Tank recently made public the first draft of its much-anticipated proposal for a ‘National IPR Policy’ (you can read the document in full here). Earlier this week, IAM’s sister publication World Trademark Review analysed…

30 April 2015

New Senate bill pushes patent reform a step closer to consensus, but there is a long way to go

The latest attempts to introduce new legislative patent reform in the US took its most significant step yesterday when the Protecting American Talent and Entrepreneurship (PATENT) Act was introduced in the Senate. With the backing of Senate…

16 February 2015

Antitrust is now firmly part of the picture for IP owners in China. Compliance is the next hurdle

Details of the Chinese National Development and Reform Commission’s settlement of its antitrust probe of Qualcomm emerged last week, with the US company slated to pay a $975 million fine and facing significant limitations on its patent licensing…

06 February 2015

India could end up trumping China as a patent dispute venue for many rights holders

China often hogs the limelight when it comes to discussion about which emerging economy will become the next major IP market alongside the United States and Europe. Questions over the Indian authorities’ approach to IP rights have no doubt…

07 July 2015

Lee hails the US’s “world class patent system”, but concedes greater clarity is needed on eligibility. Hmmm ….

USPTO Director Michelle Lee underlined her support for Congress to pass “targeted” patent reform legislation in a speech in Washington DC yesterday. She insisted that there was a role for all three branches of government to play in preserving a…

19 March 2015

As patent reform battle lines are drawn in the Senate it’s looking like a long haul

In the House of Representatives, at least, patent reform 2.0 has so far followed the expected legislative arc. Congressman Goodlatte reintroduced the Innovation Act in February and, barring a miraculous shift in support, the only serious question…

19 April 2018

Women have worse outcomes in virtually all respects when it comes to securing US patent rights, study finds

Not only do women inventors submit far fewer US patent applications than men, but they also have much greater difficulty in obtaining and maintaining rights, a new study has revealed. The first-of-its-kind research found that female applicants are…

14 June 2018

Congress given chance to reduce threat for brand-name pharma from Hatch-Waxman and IPR challenges

US Senator Orrin Hatch has introduced a legislative amendment which would prevent generic drug companies from challenging brand-name drug patents using both the Hatch-Waxman and an inter partes review (IPR) routes. Instead, they would be forced to…

23 May 2018

Oncology drives major pharma deals while immuno-oncology patent activity soars

Cancer immunotherapy is an exciting, relatively new therapy that treats cancer by unleashing the power of the immune system. It has been hailed as one of the most promising advances in the treatment of cancer in recent times. Immuno-oncology…

05 June 2018

EU set to introduce SPC manufacturing waiver, while uncertainty continues over unitary regime

The European Commission last week proposed a waiver allowing generic and biosimilar drug companies to manufacture products protected by Supplementary Protection Certificates (SPCs) for export. The proposal will meet with disapproval from pharma…

03 July 2018

HP moves into life sciences, while microfluidics market sees a surge in patent filings and suits

A new analysis of the thriving synthetic biology patent landscape has revealed the top patent owners and dealmakers in this space, as well as those appearing most often in the courtroom. Among its key findings are that Hewlett Packard (HP) has…